Opendata, web and dolomites

PRECIOUS SIGNED

Scaling-up biodegradable nanomedicines for multimodal for multimodal precision cancer immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PRECIOUS" data sheet

The following table provides information about the project.

Coordinator
STICHTING KATHOLIEKE UNIVERSITEIT 

Organization address
address: GEERT GROOTEPLEIN NOORD 9
city: NIJMEGEN
postcode: 6525 EZ
website: www.radboudumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.precious-h2020.eu
 Total cost 8˙291˙217 €
 EC max contribution 8˙291˙217 € (100%)
 Programme 1. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-NMP-2015-two-stage
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) coordinator 1˙802˙005.00
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 984˙650.00
3    ITEOS THERAPEUTICS BE (GOSSELIES) participant 952˙222.00
4    EVONIK NUTRITION & CARE GMBH DE (ESSEN) participant 838˙549.00
5    UNIVERSITAT KONSTANZ DE (KONSTANZ) participant 828˙126.00
6    SPECIALIZED MEDICAL SERVICES-ONCOLOGY BV NL (SCHIPHOL) participant 722˙689.00
7    FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI IT (Milan) participant 693˙206.00
8    ONCOARENDI THERAPEUTICS SPOLKA AKCYJNA PL (WARSZAWA) participant 617˙854.00
9    USTAV MAKROMOLEKULARNI CHEMIE AV CRVVI CZ (PRAHA 6) participant 464˙238.00
10    IOX THERAPEUTICS LIMITED UK (LONDON) participant 242˙295.00
11    TTOPSTART BV NL (UTRECHT) participant 145˙377.00

Map

 Project objective

PRECIOUS aims at scaling-up biodegradable nanomedicines for multimodal precision cancer immunotherapy. With 3.5 million cancer patients in Europe every year, new cancer medicines are eagerly awaited, notably for prostate and ovarian cancer. Systemically applied new immunotherapies are promising, but their toxicity is a hurdle. Vaccination against cancer is safe but rather the efficacy can be disappointing, i.e. the microenvironment shuts down anti-tumour immunity.

PRECIOUS will tackle 2 bottlenecks: 1. Production of non toxic multimodal nanomedicines, which induce vigorous immune responses, and at the same time reverse immunosuppression 2. Large scale GMP production of nanomedicines, and initiate a multimodal immunotherapy Phase I trial.

We want to solve these bottlenecks by: Objective 1: Two types of GMP biodegradable nanoparticles: 1) a nanovaccine, containing tumour antigens and immune activators, and 2) a nanoparticle composed of compounds, which reverses the suppression and reactivates immunity in the tumour. Objective 2: Clinical Phase I trial to show efficacy. Nanomedicines will be used by 1) injection of vaccines to evoke immune responses and 2) injection of nanoparticles in the tumour microenvironment, which slowly release compounds that reverse suppression.

To achieve this, a platform is formed with 6 leading industrial partners to produce large scale GMP nanomedicines and an excellent immunomodulator track record, together with 5 renowned academic partners to perform clinical studies. Relevance to call: Large scale GMP production, industrial leadership, nanotechnology and advanced manufacturing KET technologies, translation to the clinic, marketing development.

 Publications

year authors and title journal last update
List of publications.
2018 Giuseppe Lo Russo, Massimo Moro, Michele Sommariva, Valeria Cancila, Mattia Boeri, Giovanni Centonze, Simona Ferro, Monica Ganzinelli, Patrizia Gasparini, Veronica Huber, Massimo Milione, Luca Porcu, Claudia Proto, Giancarlo Pruneri, Diego Signorelli, Sabina Sangaletti, Lucia Sfondrini, Chiara Storti, Elena Tassi, Alberto Bardelli, Silvia Marsoni, Valter Torri, Claudio Tripodo, Mario Paolo Colombo, Andrea Anichini, Licia Rivoltini, Andrea Balsari, Gabriella Sozzi, Marina Chiara Garassino
Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
published pages: , ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-18-1390
Clinical Cancer Research 2020-02-25
2018 Veronica Huber, Viviana Vallacchi, Viktor Fleming, Xiaoying Hu, Agata Cova, Matteo Dugo, Eriomina Shahaj, Roberta Sulsenti, Elisabetta Vergani, Paola Filipazzi, Angela De Laurentiis, Luca Lalli, Lorenza Di Guardo, Roberto Patuzzo, Barbara Vergani, Elena Casiraghi, Mara Cossa, Ambra Gualeni, Valentina Bollati, Flavio Arienti, Filippo De Braud, Luigi Mariani, Antonello Villa, Peter Altevogt, Viktor Umansky, Monica Rodolfo, Licia Rivoltini
Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma
published pages: 5505-5516, ISSN: 0021-9738, DOI: 10.1172/jci98060
Journal of Clinical Investigation 128/12 2020-02-25
2016 Valerie L. Herrmann, Daniel E. Wieland, Daniel F. Legler, Valentin Wittmann, Marcus Groettrup
The STEAP1 262-270 peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice-A new approach to immunotherapy against prostate carcinoma
published pages: 456-468, ISSN: 0270-4137, DOI: 10.1002/pros.23136
The Prostate 76/5 2020-02-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRECIOUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PRECIOUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.2.)

nTRACK (2017)

Multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration

Read More  

ReSiSTant (2018)

Large Riblet Surface with Super Hardnesss, Mechanical and Temperature Resistance by Nano Functionalization

Read More  

iNanoBIT (2017)

Integration of Nano- and Biotechnology for beta-cell and islet Transplantation

Read More